🇨🇦 |Radiation Oncologist @RadMedPM @PMcancercentre @UofTdro | Alumnus @Sunnybrook @QueensOncology @JohnsHopkinsSPH @SchulichMedDent | Views = mine
Joined January 2012
- Tweets 267
- Following 463
- Followers 409
- Likes 1,469
12 Photos and videos
Michael Yan, MD MPH retweeted
May 18
So thrilled to see our collaborative publication with @tedradonc, @ma5RN and many others now online in @JCO_ASCO
These data from a large, multinational cohort provide further support for EBRT's role in the management of HCC.
ascopubs.org/doi/10.1200/JCO…
3
16
39
9,061
Michael Yan, MD MPH retweeted
May 17
Thank you @TheLancetOncol for accepting the concurrent publication of the data…. To read more see QR code here; #ESTRO26 #radonc
4
49
122
6,604
Michael Yan, MD MPH retweeted
Ablative RT often causes tissue changes within a few mm outside of the target lesion
Can give the appearance of tumor "growth" when this often is pseudoprogression
CT/MRI reports often do not reflect this possibility
Larger size does not always mean local failure!!
5
6
48
3,822
Michael Yan, MD MPH retweeted
May 5
The entire @Sunnybrook spine #SBRT team has come together to share 17 years of research and clinical observations in this review for @NatRevClinOncol. We are a true multidisciplinary team that have had a singular focus to develop the technique and evidence nature.com/articles/s41571-0…
3
46
113
4,629
1/7 🧵 New in @LancetOncology: we built a Delphi consensus on primary endpoints for MDT trials in oligometastatic cancer — because the endpoints we've been using were designed for drugs, not for ablation.
On behalf of the EORTC–ESTRO OligoCare consortium.
5
108
266
34,983
Michael Yan, MD MPH retweeted
Wow. Thank you everyone for such an amazing response to this article. 60K views in 24 hrs for an academic article in the current era of X is truly encouraging. Speaks to the “unmet need” of educational resources for critical appraisal. ascopubs.org/doi/10.1200/OP-…
A MUST-READ!
This is probably one of my most important papers where I try to teach how to fish rather than offer fish.
How I Read a Clinical Trial Report?
BG’s primer for Busy Clinicians.
Thank you @JCOOP_ASCO @EthicsdoctorP for the kind invitation. I hope the readers will find this useful.
ascopubs.org/doi/10.1200/OP-…
3
15
102
11,048
Michael Yan, MD MPH retweeted
Check out our amazing meta analysis FIRE-STORM, showing PFS significantly better with DE-RT over 66 Gy in 33 for high grade meningioma. We hope this will help as we prepare to show for over 70 Gy improves control in future trial!!
redjournal.org/article/S0360…
3
24
66
6,678
Michael Yan, MD MPH retweeted
Feb 14
Barcelona HCC classification may not reflect current treatment practices in US
The new BEACON-HCC Classification was introduced for comment today @HCCLIVEConf - pls weigh in!
Pilot real-world cases: Expert concordance 100% with BEACON-HCC vs 58.6% with 2022 #BCLC
4
68
139
9,732
Michael Yan, MD MPH retweeted
Jan 15
#HRQOL #oligoprog #SBRT
🔥RADIANT - phII oligoprog GI, GU, breast
🔵 secondary outcome - HRQOL
⬇️ mean global health SS but not clinically significant at 6m
🔵disease progression predictor of worse HRQOL on MVA
🔵if no prog HRQOL was stable or improved in 83%
1/
1
7
17
6,619
𖠣 New in @TheJNS Spine: Does timing matter? Analysis led by @MichaelYanMD @UHN found improved locoregional cancer control among patients who receive radiotherapy before vertebral augmentation for spine metastases: tinyurl.com/3k9ckx32 @UofTDRO @UofTNeuroSurge @UofTMedIm
2
6
507
Michael Yan, MD MPH retweeted
Jan 8
First prospective series to demonstrate #SBRT could induce contralateral lobe hypertrophy in #HCC
- Around 30% increase in FLR
- Fastest rate in first 3 months
- Ongoing hypertrophy until plateauing at 12 months
Full text link: redjournal.org/article/S0360…
1
19
35
8,577
Michael Yan, MD MPH retweeted
Jan 10
Excellent outcomes from HK following SBRT-IO for HCC (73% MVI, med. 11cm).
Strong rationale for phase 3 RCTs. Please support #NRG GI012 IO \- SBRT for HCC w MVI.
Jan 10
Honoured to present START-FIT x STRIDE in #ASCO #GI26
N=33, Ph2
- Median tumour size=11cm, 73% MVI ve
- Best ORR: 73% (CR: 42%) per mRECIST
- 18M LC: 96.6%, 18M OS: 90%, 18M PFS: 61.8%
- No new safety signal
SBRT-IO is promising in HCC w/ MVI
Looking forward the #NRG GI012
11
22
2,394
Michael Yan, MD MPH retweeted
Jan 10
Long-term results of Ph2 celiac plexus SRS trial (n=107)
1 dose RT (25Gy) led to 60% pain reduction & pain control for 4 mo.
Suggestion of better durability when tumor included (w plexus) in RT volume.
RCT in development. Great work Yaacov Lawrence & team! #GI26 @OncoAlert
1
28
85
3,846
Michael Yan, MD MPH retweeted
22 Dec 2025
Advanced cirrhosis (CP-B8/C) often precludes embolic bridging (Y90/TACE) in HCC, so options limited.
Small, uniquely targeted pilot study suggests SBRT could fill gap: local control 100% (40Gy/5fx), & 67% transplanted or eligible after 1 yr. @OncoAlert
redjournal.org/article/S0360…
1
19
53
4,757
27 Nov 2025
Absolute pleasure hosting @lauren_henke @APrice_BeamOn and learning from world leaders in adaptive RT. Innovative as always, and inspiration to leverage tech to move the needle and improve patient outcomes.
27 Nov 2025
Wonderful to get to visit friends @RadMedPM 🇨🇦 rep @RadOncUH w/ @APrice_BeamOn 💪🏼Hard to beat company like @ldawsonmd @j_lukovic @MichaelYanMD et al, getting to be part of their annual GI SBRT course, & even getting to talk about pancreas RT on World Pancreatic Cancer Day 💜 Thanks for having us! @caseccc @UH_RE_Institute
4
12
1,804
Our meta-analysis on the impact of biologically effective dose and dose-rate in #GammaKnife radiosurgery in trigeminal neuralgia is in @Advances_ASTRO! @MichaelYanMD @detsang @UofTDRO
30 Oct 2025
We use some 👻🎃scary high🧙♀️☠️radiation doses when treating trigeminal neuralgia (TN) to reduce those pain ⚡️jolts!
@janeJomy & team conducted this systemic review and meta-analysis of 8 publications including close to 2,600 patients!
They found:
✅higher dose rate➡️higher pain relief
✅BED may be correlated with pain relief BUT ☠️possibly related to increased sensory dysfunction
advancesradonc.org/article/S…
3
4
663
Michael Yan, MD MPH retweeted
27 Sep 2025
Psuedoprogression Radiation Necrosis vs progression new imaging techniques treating Rad Nec using Boswellia CNS PRO session #ASTRO25
2
27
78
5,485
Michael Yan, MD MPH retweeted
28 Sep 2025
#ASTRO25 MultiD Approach to HCC Choosing SBRT, Ablation, Y90
2
34
65
6,632
Michael Yan, MD MPH retweeted
19 Sep 2025
1/ 🧵 Thrilled to share that our manuscript on immune modulation during curative RT is now published in the Red Journal! sciencedirect.com/science/ar…
Here’s what we found about how RT reshapes systemic immunity (and why it may matter for distant mets)
2
10
22
2,290
Michael Yan, MD MPH retweeted
12 Sep 2025
Celiac plexus SRS for pancreatic cancer pain. Thank you to all my co-authors for the support with publishing this review
@MichaelYanMD @LawrenceYaacov @ldawsonmd
sciencedirect.com/science/ar…
4
11
457